?? What an amazing experience at #ACR24! Kyverna was thrilled to join American College of Rheumatology at ACR Convergence 2024 in Washington, DC! A special shout out to all who visited our booth and attended our symposium to learn more about how we are harnessing the power of #CARTCellTherapy for #autoimmunedisease treatment. We’re already looking forward to next year in Chicago! Stay tuned for more highlights from the conference.
Kyverna Therapeutics
生物技术研究
Emeryville，California 17,904 位关注者
Harnessing the power of cell therapy in autoimmune disease.
关于我们
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
- 网站
-
https://kyvernatx.com
Kyverna Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Emeryville，California
- 类型
- 上市公司
- 创立
- 2018
- 领域
- cell therapy、autoimmune、lupus、multiple sclerosis、systemic sclerosis、scleroderma、myasthenia gravis、CAR T-cell和stiff-person syndrome
地点
-
主要
获取路线
5980 Horton St
Suite 550
US，California，Emeryville，94608
Kyverna Therapeutics员工
动态
-
We’re gearing up for today’s symposium at #ACR24! Join us from 6:00-7:45pm for?KYV-101 Anti-CD19 CAR T-Cell Therapy: The Future of Autoimmune Disease Treatment. Discover the latest data from Kyverna and the potential of CAR T-cell therapy for #autoimmunedisease.
-
-
We are thrilled to present the latest data update from KYV-101 in the treatment of lupus nephritis patients at #ACR24. All patients with at least six months of follow-up after treatment with KYV-101 at our target dose continue to display sustained efficacy and durability across key pillars of disease. This update further establishes KYV-101’s potential to deliver significant clinical benefit with a manageable safety profile and reinforces our clinical experience with KYV-101 in lupus nephritis and other #autoimmunedisease.
-
-
Kyverna is excited to join #ACR24 in Washington, DC with the American College of Rheumatology. Visit us at booth 2802 to learn more about how we're developing #CARTCellTherapy for patients with autoimmune diseases, designed to achieve deep B cell depletion for an immune system reset. Don’t miss our symposium on 11/18 from 6:00-7:45pm and explore the future of #autoimmunedisease treatment. See you there!
-
-
Thank you to each and every #lupuswarrior, caregiver and advocate that stopped by our tent at the San Francisco Lupus Foundation of America, Inc. Walk To End Lupus Now 2024. We appreciated the opportunity to share about #cartcelltherapy and how it has the potential to change the landscape for #autoimmunedisease treatment! ????
-
-
We are proud to sponsor and attend the Lupus Foundation of America, Inc. 2024 Walk to End Lupus Now in San Francisco this Sunday, October 27th. We look forward to engaging with all of the #LupusWarriors in attendance! #CARTCellTherapy #AutoimmuneDiseases #WalkToEndLupusNow
-
-
We are excited to welcome Mert Aktar to our Board of Directors! Mert is an accomplished industry leader with over two decades of biopharmaceutical experience, melding deep technical expertise in cell and gene therapy with a proven track record in corporate strategy and business development, which will be invaluable as we seek to bring the transformative power of CAR T therapies to autoimmune patients worldwide. Welcome, Mert! #cartcelltherapy?#KYV101?#autoimmunedisease
-
-
Today, we welcomed Cara Bauer (she/her) as our new Chief Human Resources Officer! Cara is an expert in Human Resource strategy, culture building and talent development, and brings more than 25 years of experience in human resources leadership, building and scaling global organizations, most recently at Kite. Welcome, Cara!
-
-
We were thrilled to have Karen Walker represent Kyverna on the panel discussion “Accelerating Access to Cell Therapies – Streamlining Research Translation and Expedited Manufacturing Technologies" at #MeetingOnTheMesa this week.
-
-
Over the weekend, Kyverna proudly supported the 2024 Walk to End Lupus Now in New York City. It was an inspiring event by Lupus Foundation of America, Inc., bringing together patients, caregivers and advocates - all united by a shared mission to make a difference for the lupus community. We're excited to continue our involvement at the San Francisco walk later this month!
-